ProShares Ultra Nasdaq Biotechnology (BIB) Leverage/Terbalik
$109,80
▼ -0,67 (-0,61%)
Perubahan 1 hari
$62,04 – $126,40
Rentang 52 minggu
Data kepemilikan belum tersedia untuk dana ini.
BIB Grafik Harga Saham OHLCV harian dengan indikator teknis — geser, perbesar, dan sesuaikan tampilan Anda
rentang
batang
Granularitas batang menyesuaikan dengan periode yang dipilih — arahkan kursor ke bagan untuk melihat buka/tinggi/rendah/tutup untuk sebuah batang.
Performa per 2 Okt. 2026
| Periode | Imbal hasil harga | Imbal hasil total |
|---|---|---|
| 1M | ▼ -9,84% | ▼ -9,78% |
| 3M | ▲ +2,77% | ▲ +2,84% |
| 6M | ▲ +34,28% | ▲ +34,37% |
| YTD | ▲ +37,63% | ▲ +37,74% |
| 1Y | ▲ +73,21% | ▲ +73,64% |
| 3Y | ▲ +135,47% | ▲ +142,03% |
| 5Y | ▲ +20,16% | ▲ +23,54% |
| Maks | ▲ +1362,31% | ▲ +1406,10% |
Volatilitas 1T42,75%
Volatilitas 3Y41,86%
Penurunan Maksimum 3Y
-45,99%
Beta 3Y0,85
Sharpe 1Y*1,50
Total pengembalian mengasumsikan dividen diinvestasikan kembali. Pengembalian tidak dibandingkan dengan indeks. * Rasio Sharpe dihitung dengan suku bunga bebas risiko 0%.
Aliran dana (dilaporkan SEC)
Bulan lalu (Mei 2026)
-$4.8M
Kuartal berakhir Mei 2026
-$13.9M
12 bulan terakhir
-$12.0M
Based on the fund's own SEC Form N-PORT monthly flow disclosures (Item C.9 "Flow Information") — sales minus redemptions, reinvested distributions excluded. This is a different, independent metric from the "Net flows" estimate above (which is derived from daily shares-outstanding changes). SEC N-PORT filing lag is up to ~60 days; the most recent month/quarter may not yet be fully reflected.
Komposisi Penuh 267 saham
| Nama | CUSIP | Nilai | % | Saldo | Kategori | Negara |
|---|---|---|---|---|---|---|
| Sekuritas tidak diketahui | · | $5.4M | 7,35 | 3.524 | DE | US |
| ProShares GENIUS Money Market ETF | 74350P691 | $5.0M | 6,80 | 50.000 | OTHER | US |
| Gilead Sciences, Inc. | 375558103 | $3.4M | 4,66 | 25.542 | EC | US |
| Vertex Pharmaceuticals, Inc. | 92532F100 | $3.4M | 4,65 | 7.657 | EC | US |
| Amgen, Inc. | 031162100 | $3.3M | 4,48 | 9.803 | EC | US |
| Sekuritas tidak diketahui | · | $2.9M | 3,94 | 2.513 | DE | US |
| Sekuritas tidak diketahui | · | $2.4M | 3,26 | 2.639 | DE | US |
| Regeneron Pharmaceuticals, Inc. | 75886F107 | $2.4M | 3,21 | 3.840 | EC | US |
| Sekuritas tidak diketahui | · | $1.9M | 2,62 | 3.374 | DE | US |
| Alnylam Pharmaceuticals, Inc. | 02043Q107 | $1.5M | 2,01 | 4.904 | EC | US |
| Revolution Medicines, Inc. | 76155X100 | $1.2M | 1,57 | 7.326 | EC | US |
| Biogen, Inc. | 09062X103 | $1.1M | 1,44 | 5.425 | EC | US |
| Repurchase Agreement | · | $945K | 1,28 | 944.611 | RA | US |
| Illumina, Inc. | 452327109 | $921K | 1,25 | 5.653 | EC | US |
| United Therapeutics Corp. | 91307C102 | $902K | 1,22 | 1.620 | EC | US |
| Royalty Pharma plc | · | $883K | 1,20 | 15.837 | EC | GB |
| Argenx SE | 04016X101 | $878K | 1,19 | 1.050 | EC | NL |
| Sekuritas tidak diketahui | · | $871K | 1,18 | 4.232 | DE | US |
| Insmed, Inc. | 457669307 | $852K | 1,16 | 7.968 | EC | US |
| Roivant Sciences Ltd. | · | $794K | 1,08 | 26.460 | EC | BM |
| Incyte Corp. | 45337C102 | $712K | 0,97 | 7.359 | EC | US |
| Viatris, Inc. | 92556V106 | $692K | 0,94 | 42.565 | EC | US |
| Moderna, Inc. | 60770K107 | $689K | 0,94 | 14.600 | EC | US |
| Guardant Health, Inc. | 40131M109 | $629K | 0,85 | 4.850 | EC | US |
| INVESCO GOVT AND AGCY LEX | 825252885 | $598K | 0,81 | 598.016 | STIV | US |
| Repurchase Agreement | · | $594K | 0,81 | 594.435 | RA | US |
| Neurocrine Biosciences, Inc. | 64125C109 | $588K | 0,80 | 3.712 | EC | US |
| Jazz Pharmaceuticals plc | · | $538K | 0,73 | 2.275 | EC | IE |
| Ascendis Pharma A/S | · | $510K | 0,69 | 2.276 | EC | DK |
| Summit Therapeutics, Inc. | 86627T108 | $503K | 0,68 | 28.664 | EC | US |
| Exelixis, Inc. | 30161Q104 | $485K | 0,66 | 9.600 | EC | US |
| Bridgebio Pharma, Inc. | 10806X102 | $475K | 0,64 | 7.167 | EC | US |
| Medpace Holdings, Inc. | 58506Q109 | $470K | 0,64 | 1.051 | EC | US |
| Ionis Pharmaceuticals, Inc. | 462222100 | $467K | 0,63 | 6.109 | EC | US |
| Repurchase Agreement | · | $446K | 0,61 | 445.826 | RA | US |
| Axsome Therapeutics, Inc. | 05464T104 | $443K | 0,60 | 1.890 | EC | US |
| Madrigal Pharmaceuticals, Inc. | 558868105 | $421K | 0,57 | 847 | EC | US |
| BioMarin Pharmaceutical, Inc. | 09061G101 | $407K | 0,55 | 7.110 | EC | US |
| BioNTech SE | 09075V102 | $404K | 0,55 | 4.213 | EC | DE |
| Arrowhead Pharmaceuticals, Inc. | 04280A100 | $403K | 0,55 | 5.178 | EC | US |
| Sanofi SA | 80105N105 | $395K | 0,54 | 9.047 | EC | FR |
| Praxis Precision Medicines, Inc. | 74006W207 | $360K | 0,49 | 1.029 | EC | US |
| Cytokinetics, Inc. | 23282W605 | $349K | 0,47 | 4.553 | EC | US |
| BeOne Medicines Ltd. | 07725L102 | $340K | 0,46 | 1.181 | EC | CH |
| Krystal Biotech, Inc. | 501147102 | $334K | 0,45 | 1.080 | EC | US |
| Repurchase Agreement | · | $327K | 0,44 | 326.939 | RA | US |
| Tempus AI, Inc. | 88023B103 | $324K | 0,44 | 6.424 | EC | US |
| Abivax SA | 00370M103 | $301K | 0,41 | 2.271 | EC | FR |
| Nuvalent, Inc. | 670703107 | $299K | 0,41 | 2.705 | EC | US |
| Halozyme Therapeutics, Inc. | 40637H109 | $290K | 0,39 | 4.364 | EC | US |
Dividen 13 pembayaran
0,20%Imbal hasil TTM
$0,23Pembayaran TTM / saham
Kuartalan
(est.)
| Tanggal ex-dividen | Jumlah / saham |
|---|---|
| 23 Sep. 2026 | $0,0830 |
| 25 Maret 2026 | $0,0070 |
| 24 Des. 2025 | $0,1350 |
| 24 Sep. 2025 | $0,1810 |
| 25 Juni 2025 | $0,1710 |
| 26 Maret 2025 | $0,1310 |
| 23 Des. 2024 | $0,3960 |
| 25 Sep. 2024 | $0,1530 |
| 26 Juni 2024 | $0,2650 |
| 20 Maret 2024 | $0,0400 |
| 20 Des. 2023 | $0,0380 |
| 22 Des. 2022 | $0,0200 |
| 21 Sep. 2010 | $0,0110 |
Pemilik institusional (13F) 22 pengaju
Institusi yang melaporkan kepemilikan ETF ini dalam Formulir SEC 13F triwulanan mereka. Hanya posisi long; satu pengaju dapat muncul dua kali untuk leg opsi terpisah. Kaki put/call offset yang besar biasanya mencerminkan pembuatan pasar atau inventaris yang dilindungi, bukan keyakinan arah.
| Institusi | Nilai | % dari 13F yang dilacak | Saham | Tipe | Per tanggal |
|---|---|---|---|---|---|
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $785.973 | 21,94% | 7.802 | Saham | 30 Juni 2026 |
| Capital Investment Advisors, LLC | $599.013 | 16,72% | 5.946 | Saham | 30 Juni 2026 |
| Kaizen Financial Strategies | $535.554 | 14,95% | 5.315 | Saham | 30 Juni 2026 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $413.034 | 11,53% | 4.100 | Opsi beli | 30 Juni 2026 |
| Palumbo Wealth Management LLC | $402.960 | 11,25% | 4.000 | Saham | 30 Juni 2026 |
| CITADEL ADVISORS LLC | $302.220 | 8,44% | 3.000 | Opsi beli | 30 Juni 2026 |
| Jump Financial, LLC | $257.189 | 7,18% | 2.553 | Saham | 30 Juni 2026 |
| TOTH FINANCIAL ADVISORY CORP | $102.957 | 2,87% | 1.022 | Saham | 30 Juni 2026 |
| FRANKLIN RESOURCES INC | $70.115 | 1,96% | 696 | Saham | 30 Juni 2026 |
| PNC Financial Services Group, Inc. | $50.370 | 1,41% | 500 | Saham | 30 Juni 2026 |
| Ashton Thomas Private Wealth, LLC | $37.576 | 1,05% | 373 | Saham | 30 Juni 2026 |
| Truvestments Capital LLC | $12.593 | 0,35% | 125 | Saham | 30 Juni 2026 |
| Axiom Investment Management LLC | $5.037 | 0,14% | 50 | Saham | 30 Juni 2026 |
| Qube Research & Technologies Ltd | $4.936 | 0,14% | 49 | Saham | 30 Juni 2026 |
| SIMPLEX TRADING, LLC | $1.309 | 0,04% | 13 | Saham | 30 Juni 2026 |
| CHASE INVESTMENT COUNSEL CORP | $241 | 0,01% | 2.400 | Saham | 30 Juni 2026 |
| Rockefeller Capital Management L.P. | $201 | 0,01% | 2 | Saham | 30 Juni 2026 |
| MORGAN STANLEY | $131 | 0,00% | 1 | Saham | 30 Juni 2026 |
| UBS Group AG | $101 | 0,00% | 1 | Saham | 30 Juni 2026 |
| WELLS FARGO & COMPANY/MN | $65 | 0,00% | 1 | Saham | 30 Juni 2026 |
| Harel Insurance Investments & Financial Services Ltd. | $20 | 0,00% | 198 | Saham | 30 Juni 2026 |
| ROYAL BANK OF CANADA | $0 | 0,00% | 1 | Saham | 30 Juni 2026 |